Amorphous solid form of a BET protein inhibitor
US10858372B2 · kind B2 · utility
8Cited by
27References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2019 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | May 29, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.